Herceptin News and Research

RSS

Trastuzumab-DM1 - a 'smart bomb' for breast cancer treatment

Sarah Cannon Research Institute (SCRI) investigators have found that "smart bomb" therapies are effective in treating breast cancer patients while minimizing side effects.

7 Sep 2008

New research finds way to switch off breast cancer and leukaemia

Australian scientists have identified a way of switching off a molecule, which plays a key role in the process that triggers breast cancer and certain forms of leukaemia.

11 Aug 2008

Gab2 signalling protein switches off breast cancer and leukaemia

Australian scientists have identified a way to 'switch off' a molecule, a key player in the molecular processes that trigger breast cancer and certain forms of leukaemia.

10 Aug 2008

Laboratory and mouse studies show targeted drug blocks the growth of breast cancer cells that spread to the brain

Using laboratory and mouse models of human breast cancer, researchers have found that a small molecule capable of targeting specific proteins on the surface of breast cancer cells can inhibit the growth of breast cancer cells that migrate to the brain.

29 Jul 2008

FDA approves novel genetic test for patients with breast cancer

The U.S. Food and Drug Administration has approved a novel genetic test for determining whether patients with breast cancer are good candidates for treatment with the drug Herceptin (trastuzumab).

8 Jul 2008

Report says cancer clinicians should understand and consider the economic impact of new interventions

Cancer clinicians should understand and consider the economic impact of new interventions, which often have substantial costs, according to a report appearing in the July/August issue of CA: A Cancer Journal for Clinicians, a peer-reviewed journal of the American Cancer Society.

2 Jul 2008

New breast cancer drug combo shrinks aggressive tumours

An international trial of a new breast cancer drug has shown the drug is able to shrink tumours caused by one of the most aggressive forms of the disease.

2 Jun 2008

First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early breast cancer

A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.

27 May 2008

Combo of Herceptin and chemo a cure for breast cancer

The latest research has shown that the combination of Herceptin and chemotherapy drugs is successful in treating women with aggressive breast cancer.

22 Apr 2008

Herceptin and chemotherapy improves response rates without major adverse effects in HER2 breast cancer

Women with a particularly aggressive form of breast cancer seem to do better if they are treated with a combined anthracycline and taxane chemotherapy regimen before surgery, together with trastuzumab (Herceptin) before and after surgery, according to results from the largest multi-centre trial to investigate this treatment.

18 Apr 2008

Double binding sites on tumor target may provide future combination therapy

Researchers from the University of Pennsylvania School of Medicine and colleagues at Merck Serono Research in Germany have found that two drugs bind to receptor sites on some tumors in different places at the same time, suggesting the possibility of a new combination therapy for certain types of cancer.

9 Apr 2008

Benefits of some cancer drugs exaggerated because trials were stopped early

Italian scientists say the benefits of some cancer drugs may be exaggerated as a rising number of trials are stopped early.

9 Apr 2008

Cardiac effects associated with breast cancer treatment appear lower with dose-dense chemotherapy

A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a "dose-dense" regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin), a drug that has previously been shown to cause cardiac toxicity.

11 Mar 2008

Cardiac effects associated with breast cancer treatment appear lower

A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a “dose-dense” regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin®), a drug that has previously been shown to cause cardiac toxicity.

10 Mar 2008

New global study of targeted therapies for breast cancer

Two targeted medications designed to treat an aggressive form of breast cancer are being tested in a new study involving 8,000 participants in 50 countries across six continents -- a clinical trial that investigators hope will provide a new model for global cancer research.

1 Mar 2008

Black women get breast cancer two decades earlier than white women

Black British women in Hackney, East London, are diagnosed with breast cancer 21 years younger than white British women, according to a Cancer Research UK study published online in the British Journal of Cancer.

17 Jan 2008

Survival shortened when estrogen or progesterone receptor negative breast cancer spreads to the brain

Two studies from Mayo Clinic's site in Jacksonville, Fla., of women whose breast cancer spread to their brain, have found that women whose tumors do not have estrogen or progesterone receptors have the worst overall outcomes.

17 Dec 2007

Herceptin helps women with multiple chromosomes containing HER2 gene

The targeted therapy Herceptin helps women with HER2+ type of breast cancer independent of whether patients have extra copies of chromosome 17, home to the HER2 gene which produces the HER2 protein that fuels cancer growth.

17 Dec 2007

Tumors less than 1 centimeter in size can be aggressive and may require maximum therapy

Breast tumors that are 1 centimeter in size or smaller - no more than 0.4 inch in length - can still be very aggressive and may require more intensive therapy than is routinely offered today, say researchers at Mayo Clinic in Jacksonville, Fla.

17 Dec 2007

Targeted therapy and chemotherapy shrinks breast cancer metastases in brain

A combination of a "targeted" therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber Cancer Institute investigators at the San Antonio Breast Cancer Symposium.

17 Dec 2007